Recent research inferred that a drug inducing Dysferlin expression in myocytes could represent a targeted during clinical treatment for Dysferlinopathy patients (Kokubu et al., 2019), which also indicates that gene therapy could be an effective future clinical avenue for MMD patients. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.